by ASTCT
How can transplant and cellular therapy programs effectively integrate geriatric assessment into clinical practice? Based on expert insights from a recent ASTCT webinar, this infographic series...
by Claudio G. Brunstein, MD
Claudio G. Brunstein, MD, vice chair of Hematology and Oncology at Cleveland Clinic’s Taussig Cancer Institute, shares how his early exposure to blood and marrow transplantation inspired a...
by Transplantation and Cellular Therapy
Efmarodocokin alfa, an interleukin-22 agonist, demonstrates potential as prophylaxis against acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation...
by Transplantation and Cellular Therapy
A retrospective study underscores the value of contemporary grading systems for interpreting post–chimeric antigen receptor (CAR) T-cell therapy outcomes.
by Clinical Cancer Research
Scientists are encouraged by early findings that point to preferentially expressed antigen in melanoma (PRAME) as a feasible alternative to usual chimeric antigen receptor (CAR) T-cell therapy for...
by Cytotherapy
Regulatory T-cells (Tregs), especially when modified to express a chimeric antigen receptor (CAR), are attracting attention for their potential therapeutic value in the setting of autoimmune,...